Catherine Schulte
Stock Analyst at Baird
(3.62)
# 573
Out of 5,182 analysts
136
Total ratings
53.04%
Success rate
5.33%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $653 → $639 | $468.04 | +36.53% | 29 | Apr 24, 2026 | |
| DHR Danaher | Maintains: Outperform | $249 → $245 | $180.62 | +35.64% | 13 | Apr 22, 2026 | |
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $19.93 | +40.49% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $55.02 | +49.04% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $52.68 | +12.00% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $88.50 | +35.59% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $115.62 | +42.71% | 18 | Nov 25, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $7.97 | +113.30% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,274.70 | -3.51% | 10 | Aug 4, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $3 → $2 | $3.68 | -45.65% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $38.09 | +7.51% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $55.11 | +23.39% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $24.98 | +52.12% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $61.00 | -45.90% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $128.52 | +118.64% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $299.79 | -27.62% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $204.39 | -90.21% | 1 | Jun 28, 2018 |
Thermo Fisher Scientific
Apr 24, 2026
Maintains: Outperform
Price Target: $653 → $639
Current: $468.04
Upside: +36.53%
Danaher
Apr 22, 2026
Maintains: Outperform
Price Target: $249 → $245
Current: $180.62
Upside: +35.64%
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $19.93
Upside: +40.49%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $55.02
Upside: +49.04%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $52.68
Upside: +12.00%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $88.50
Upside: +35.59%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $115.62
Upside: +42.71%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $7.97
Upside: +113.30%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,274.70
Upside: -3.51%
Maravai LifeSciences Holdings
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $3.68
Upside: -45.65%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $38.09
Upside: +7.51%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $55.11
Upside: +23.39%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $24.98
Upside: +52.12%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $61.00
Upside: -45.90%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $128.52
Upside: +118.64%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $299.79
Upside: -27.62%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $204.39
Upside: -90.21%